NIH R01 · 2025
T-cell plasticity mediating treatment resistance and side effects in atopic dermatitis
PROJECT SUMMARY Type 2 inflammation is mediated by a specific branch of the immune system, assumed to have developed as a major defense mechanism against parasitic infections and infestations. However, in our modern lifestyle, this kind of immune axis is mostly encountered in the context of pathological activation, especially in inflammatory diseases such as atopic dermatitis (AD). Consistently, the type 2 blocking antibody dupilumab was the first targeted FDA-approved treatment for AD. However, only 50% of patients achieved a 75% improvement in their skin scores upon dupilumab treatment during phase III clinical trials, and 10% even develop de novo paradoxical inflammatory side effects…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.